دورية أكاديمية
Aspergillus fumigatus-a systematic review to inform the World Health Organization priority list of fungal pathogens.
| العنوان: | Aspergillus fumigatus-a systematic review to inform the World Health Organization priority list of fungal pathogens. |
|---|---|
| المؤلفون: | Morrissey CO; Department of Infectious Diseases, Alfred Health and Monash University, Melbourne, Victoria, Australia., Kim HY; The University of Sydney Infectious Diseases Institute (Sydney ID), New South Wales, Australia.; Faculty of Medicine and Health, School of Pharmacy, The University of Sydney, New South Wales, Australia.; Westmead Hospital, Westmead, New South Wales, Australia., Duong TN; The University of Sydney Infectious Diseases Institute (Sydney ID), New South Wales, Australia., Moran E; Sinclair Dermatology, East Melbourne, Victoria, Australia., Alastruey-Izquierdo A; Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain., Denning DW; Global Action for Fungal Infections, Geneva, Switzerland.; Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK., Perfect JR; Division of Infectious Diseases and International Health, Duke University School of Medicine, Durham, NC, USA., Nucci M; Universidade Federal do Rio de Janeiro and Grupo Oncoclinicas, Rio de Janeiro, RJ, Brazil., Chakrabarti A; Doodhadhari Burfani Hospital and Research Institute, Haridwar, India., Rickerts V; Robert Koch Institute Berlin, FG16, Seestrasse 10, 13353 Berlin, Germany., Chiller TM; Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA., Wahyuningsih R; Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.; Department of Parasitology, Faculty of Medicine, Universitas Kristen, Jakarta, Indonesia., Hamers RL; Oxford University Clinical Research Unit Indonesia, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Cassini A; Infectious Diseases Service, Lausanne University Hospital, Lausanne, Switzerland.; Public Health Department, Canton of Vaud, Lausanne, Switzerland., Gigante V; AMR Division, World Health Organization, Geneva, Switzerland., Sati H; AMR Division, World Health Organization, Geneva, Switzerland., Alffenaar JW; The University of Sydney Infectious Diseases Institute (Sydney ID), New South Wales, Australia.; Faculty of Medicine and Health, School of Pharmacy, The University of Sydney, New South Wales, Australia.; Westmead Hospital, Westmead, New South Wales, Australia., Beardsley J; The University of Sydney Infectious Diseases Institute (Sydney ID), New South Wales, Australia.; Westmead Institute for Medical Research, Westmead, New South Wales, Australia. |
| المصدر: | Medical mycology [Med Mycol] 2024 Jun 27; Vol. 62 (6). |
| نوع المنشور: | Systematic Review; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9815835 Publication Model: Print Cited Medium: Internet ISSN: 1460-2709 (Electronic) Linking ISSN: 13693786 NLM ISO Abbreviation: Med Mycol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2014- : Oxford : Oxford University Press Original Publication: Oxford : Blackwell Science, c1998- |
| مواضيع طبية MeSH: | Aspergillus fumigatus*/drug effects , Antifungal Agents*/pharmacology , Antifungal Agents*/therapeutic use , Aspergillosis*/epidemiology , Aspergillosis*/microbiology , Aspergillosis*/mortality , World Health Organization* , Drug Resistance, Fungal*, Humans ; Voriconazole/pharmacology ; Voriconazole/therapeutic use ; Incidence ; Microbial Sensitivity Tests ; Invasive Fungal Infections/epidemiology ; Invasive Fungal Infections/microbiology ; Invasive Fungal Infections/mortality ; Invasive Fungal Infections/drug therapy ; Risk Factors |
| مستخلص: | Recognizing the growing global burden of fungal infections, the World Health Organization established a process to develop a priority list of fungal pathogens (FPPL). In this systematic review, we aimed to evaluate the epidemiology and impact of invasive infections caused by Aspergillus fumigatus to inform the first FPPL. The pre-specified criteria of mortality, inpatient care, complications and sequelae, antifungal susceptibility, risk factors, preventability, annual incidence, global distribution, and emergence were used to search for relevant articles between 1 January 2016 and 10 June 2021. Overall, 49 studies were eligible for inclusion. Azole antifungal susceptibility varied according to geographical regions. Voriconazole susceptibility rates of 22.2% were reported from the Netherlands, whereas in Brazil, Korea, India, China, and the UK, voriconazole susceptibility rates were 76%, 94.7%, 96.9%, 98.6%, and 99.7%, respectively. Cross-resistance was common with 85%, 92.8%, and 100% of voriconazole-resistant A. fumigatus isolates also resistant to itraconazole, posaconazole, and isavuconazole, respectively. The incidence of invasive aspergillosis (IA) in patients with acute leukemia was estimated at 5.84/100 patients. Six-week mortality rates in IA cases ranged from 31% to 36%. Azole resistance and hematological malignancy were poor prognostic factors. Twelve-week mortality rates were significantly higher in voriconazole-resistant than in voriconazole-susceptible IA cases (12/22 [54.5%] vs. 27/88 [30.7%]; P = .035), and hematology patients with IA had significantly higher mortality rates compared with solid-malignancy cases who had IA (65/217 [30%] vs. 14/78 [18%]; P = .04). Carefully designed surveillance studies linking laboratory and clinical data are required to better inform future FPPL. (© The Author(s) 2023. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.) |
| References: | Antimicrob Agents Chemother. 2018 Mar 27;62(4):. (PMID: 29437624) Emerg Infect Dis. 2015 Jun;21(6):1041-4. (PMID: 25988348) Ann Thorac Surg. 1997 Nov;64(5):1441-7. (PMID: 9386718) Emerg Infect Dis. 2020 Apr;26(4):804-806. (PMID: 32186508) J Antimicrob Chemother. 2018 May 1;73(5):1389-1394. (PMID: 29394399) J Antimicrob Chemother. 2018 Sep 1;73(9):2347-2351. (PMID: 29846581) Med Mycol. 2019 Nov 1;57(8):997-1003. (PMID: 30690480) J Clin Microbiol. 2017 Aug;55(8):2391-2399. (PMID: 28515220) Euro Surveill. 2016 Jul 28;21(30):. (PMID: 27541498) J Clin Epidemiol. 2013 Apr;66(4):408-14. (PMID: 23337781) Clin Infect Dis. 2017 Jul 15;65(2):216-225. (PMID: 28379304) Int J Antimicrob Agents. 2017 Feb;49(2):218-223. (PMID: 27989379) Am J Respir Crit Care Med. 2012 Jul 1;186(1):56-64. (PMID: 22517788) World J Clin Cases. 2018 Dec 26;6(16):1155-1159. (PMID: 30613674) Pharmacoepidemiol Drug Saf. 2017 Dec;26(12):1483-1491. (PMID: 28696023) Med Mycol. 2021 Apr 6;59(4):327-334. (PMID: 32642756) PLoS One. 2012;7(11):e50034. (PMID: 23226235) Lancet Respir Med. 2020 Jun;8(6):e48-e49. (PMID: 32445626) J Clin Microbiol. 2010 Apr;48(4):1478-80. (PMID: 20107096) J Fungi (Basel). 2020 Jul 10;6(3):. (PMID: 32664423) Lancet Respir Med. 2022 Feb;10(2):180-190. (PMID: 34843666) Clin Infect Dis. 2019 Apr 24;68(9):1463-1471. (PMID: 30307492) J Antimicrob Chemother. 2019 Sep 1;74(9):2759-2766. (PMID: 31236587) Clin Infect Dis. 2022 Jan 7;74(1):83-91. (PMID: 33693551) Ann Intensive Care. 2020 Jun 1;10(1):71. (PMID: 32488446) Mycoses. 2018 Jan;61(1):30-34. (PMID: 28922487) Clin Microbiol Infect. 2016 Jun;22(6):570.e1-9. (PMID: 27091095) J Antimicrob Chemother. 2018 Aug 1;73(8):2047-2053. (PMID: 29684150) Lancet Infect Dis. 2021 Jun;21(6):e149-e162. (PMID: 33333012) Med Mycol. 2020 Jan 1;58(1):54-60. (PMID: 31329931) Infection. 2018 Oct;46(5):701-704. (PMID: 29971692) Crit Care. 2021 Sep 15;25(1):335. (PMID: 34526087) Mycoses. 2016 Feb;59(2):101-7. (PMID: 26648179) Antimicrob Agents Chemother. 2012 Jul;56(7):3905-10. (PMID: 22526309) Antimicrob Agents Chemother. 2018 Aug 27;62(9):. (PMID: 29941643) J Cyst Fibros. 2017 Jan;16(1):64-69. (PMID: 27356848) Cancer Cell. 2017 Jun 12;31(6):833-843.e5. (PMID: 28552327) Med Mycol. 2017 Nov 1;55(8):803-812. (PMID: 28431001) BMJ. 2021 Mar 29;372:n71. (PMID: 33782057) Chin Med J (Engl). 2017 Mar 20;130(6):665-668. (PMID: 28303848) Front Microbiol. 2016 Jul 29;7:1164. (PMID: 27524978) J Maxillofac Oral Surg. 2019 Jun;18(2):164-179. (PMID: 30996535) Am J Respir Crit Care Med. 2020 Jul 1;202(1):132-135. (PMID: 32396381) J Antimicrob Chemother. 2019 Jul 1;74(7):1884-1889. (PMID: 31038164) Mycoses. 2014 Sep;57 Suppl 2:1-14. (PMID: 25186615) Clin Infect Dis. 2008 Nov 1;47(9):1176-84. (PMID: 18808352) Antimicrob Agents Chemother. 2017 Oct 24;61(11):. (PMID: 28893772) Pathogens. 2021 May 23;10(6):. (PMID: 34071092) J Comp Eff Res. 2020 Jun;9(8):573-584. (PMID: 32316748) Nucleic Acids Res. 2012 Jan;40(Database issue):D136-43. (PMID: 22139910) Emerg Infect Dis. 2021;27(4):1077-1086. (PMID: 33539721) Oxf Med Case Reports. 2020 Mar 30;2020(3):omz147. (PMID: 32257253) Antimicrob Agents Chemother. 2018 Jul 27;62(8):. (PMID: 29891597) Chron Respir Dis. 2018 Aug;15(3):279-285. (PMID: 29519142) Infect Drug Resist. 2018 Sep 20;11:1549-1555. (PMID: 30288065) Med Mycol. 2005 May;43 Suppl 1:S207-38. (PMID: 16110814) J Med Microbiol. 2016 Jun;65(6):468-475. (PMID: 27008655) Clin Infect Dis. 2009 Feb 1;48(3):265-73. (PMID: 19115967) J Antimicrob Chemother. 2013 Jul;68(7):1486-96. (PMID: 23580559) Value Health. 2016 Jan;19(1):1-13. (PMID: 26797229) Front Microbiol. 2018 Sep 20;9:2234. (PMID: 30294314) Drugs. 2017 Apr;77(6):599-613. (PMID: 28236169) Biol Blood Marrow Transplant. 2007 Dec;13(12):1487-98. (PMID: 18022579) Iran J Public Health. 2018 Jul;47(7):994-1000. (PMID: 30181998) mBio. 2019 Apr 2;10(2):. (PMID: 30940706) Clin Microbiol Infect. 2020 Aug;26(8):1091.e1-1091.e7. (PMID: 31901491) Emerg Microbes Infect. 2017 Dec 6;6(12):e109. (PMID: 29209054) J Clin Microbiol. 2015 Jul;53(7):2115-21. (PMID: 25903571) Clin Microbiol Rev. 2019 Nov 13;33(1):. (PMID: 31722890) J Clin Microbiol. 2015 Sep;53(9):2832-7. (PMID: 26085618) Clin Infect Dis. 2010 Apr 15;50(8):1101-11. (PMID: 20218876) J Antimicrob Chemother. 2017 Nov 01;72(11):3047-3050. (PMID: 28961889) Clin Microbiol Infect. 2020 Dec;26(12):1706-1708. (PMID: 32659385) J Antimicrob Chemother. 2013 Jul;68(7):1497-504. (PMID: 23463213) J Clin Microbiol. 2019 Jun 25;57(7):. (PMID: 31018982) Antimicrob Agents Chemother. 2017 Feb 23;61(3):. (PMID: 28052853) Antimicrob Agents Chemother. 2011 May;55(5):1953-60. (PMID: 21357302) J Antimicrob Chemother. 2016 Dec;71(12):3528-3535. (PMID: 27530755) Antimicrob Agents Chemother. 2017 Sep 22;61(10):. (PMID: 28784671) Clin Infect Dis. 2020 Oct 23;71(7):1764-1767. (PMID: 31905234) J Fungi (Basel). 2022 Jan 19;8(2):. (PMID: 35205852) BMJ. 2019 Aug 28;366:l4898. (PMID: 31462531) Int J Antimicrob Agents. 2018 Nov;52(5):637-642. (PMID: 30103005) Med Mycol. 2018 Jan 1;56(1):121-124. (PMID: 28340159) J Clin Microbiol. 2015 Mar;53(3):868-74. (PMID: 25568431) Front Cell Infect Microbiol. 2021 Feb 18;10:613774. (PMID: 33680981) Diagn Microbiol Infect Dis. 2020 May;97(1):115007. (PMID: 32081523) J Hosp Infect. 2020 Mar;104(3):358-364. (PMID: 31585141) J Clin Microbiol. 2017 Aug;55(8):2356-2366. (PMID: 28515217) Lancet Infect Dis. 2017 Dec;17(12):e383-e392. (PMID: 28774698) Clin Infect Dis. 2011 May;52(9):1123-9. (PMID: 21467016) Nat Rev Microbiol. 2023 Apr;21(4):211-212. (PMID: 36747091) J Clin Microbiol. 2017 Nov;55(11):3210-3218. (PMID: 28814586) J Clin Microbiol. 2005 Feb;43(2):906-8. (PMID: 15695702) Front Microbiol. 2018 Jul 23;9:1656. (PMID: 30083151) Haematologica. 2011 Feb;96(2):337-41. (PMID: 21071502) Clin Infect Dis. 2018 Aug 16;67(5):687-692. (PMID: 29509845) Mycoses. 2018 Jun;61(6):360-365. (PMID: 29468746) J Antimicrob Chemother. 2020 Apr 1;75(4):849-858. (PMID: 31891387) PLoS One. 2014 Jul 29;9(7):e103113. (PMID: 25072733) Emerg Infect Dis. 2020 Jul;26(7):1447-1455. (PMID: 32568033) Lancet. 2021 Feb 6;397(10273):499-509. (PMID: 33549194) J Antimicrob Chemother. 2018 Jan 01;73(1):134-142. (PMID: 29048485) Surg Infect (Larchmt). 2018 Oct;19(7):667-671. (PMID: 30227087) Antimicrob Agents Chemother. 2016 Sep 23;60(10):5878-84. (PMID: 27431231) PLoS Med. 2008 Nov 11;5(11):e219. (PMID: 18998768) Crit Care. 2015 Apr 17;19:178. (PMID: 25927915) Blood. 2018 Apr 26;131(17):1955-1959. (PMID: 29437588) J Clin Microbiol. 2020 Dec 17;59(1):. (PMID: 33087440) Lancet. 2016 Feb 20;387(10020):760-9. (PMID: 26684607) |
| معلومات مُعتمدة: | 001 International WHO_ World Health Organization; Ministry of Education and Science |
| فهرسة مساهمة: | Keywords: Aspergillus fumigatus; epidemiology; incidence; invasive aspergillosis; invasive fungal disease; mortality; risk factors; susceptibility |
| المشرفين على المادة: | 0 (Antifungal Agents) JFU09I87TR (Voriconazole) |
| تواريخ الأحداث: | Date Created: 20240627 Date Completed: 20240627 Latest Revision: 20240720 |
| رمز التحديث: | 20240720 |
| مُعرف محوري في PubMed: | PMC11210617 |
| DOI: | 10.1093/mmy/myad129 |
| PMID: | 38935907 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1460-2709 |
|---|---|
| DOI: | 10.1093/mmy/myad129 |